Mylan gets favorable court decision in Biogen’s Tecfidera patent case
Dutch generic drugmaker Mylan said that the US District Court for the Northern District of West Virginia has invalidated Biogen's Tecfidera patent U.S. Patent No. ... Read More
Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to acquire Nightstar Therapeutics, a UK-based clinical-stage gene ... Read More
Biogen strikes $600m deal with Pfizer for promising schizophrenia drug
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer's neurology drug candidate, PF-04958242, which is being developed to address cognitive ... Read More